AP101 (Oleogel S-10)
AP101 (Oleogel S-10) is being developed as a prescription medicine for Epidermolysis Bullosa (EB), for which there are severely limited treatment options. It is currently in an investigational global Phase III clinical trial for this indication; however, it has already been approved in Europe for use in the treatment of partial thickness wounds (PTW) in adults.
It is a topical product, to be applied to the skin, incorporating a betulin-based active formulated with sunflower oil. AP101 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and to differentiate into mature epithelial skin cells, thereby ensuring more rapid wound healing.